Massachusetts Financial Services Co. MA Has $40.15 Million Position in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Massachusetts Financial Services Co. increased its stake in Prestige Consumer Healthcare by 10.2% in Q4 to 650,793 shares, valued at about $40.15 million and representing 1.35% of the company.
• Prestige reported Q results of $1.14 EPS (vs. $1.16 consensus) and $283.44M revenue (vs. $286.93M), with revenue down 2.4% YoY and FY2026 guidance set at 4.54 EPS; analysts' consensus is a Hold with an average target of $76.50.
• The stock has a market cap of $2.68 billion and a P/E of 14.98, a 12‑month range of $51.24–$89.37, and is heavily institutionally owned (about 99.95%) while insiders hold roughly 1.40%.

Massachusetts Financial Services Co. MA lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 650,793 shares of the company's stock after purchasing an additional 60,496 shares during the quarter. Massachusetts Financial Services Co. MA owned 1.35% of Prestige Consumer Healthcare worth $40,147,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PBH. First Horizon Corp acquired a new stake in Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company's stock worth $34,000 after buying an additional 283 shares in the last quarter. Danske Bank A S bought a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at $37,000. Hantz Financial Services Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 373.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company's stock valued at $43,000 after acquiring an additional 538 shares in the last quarter. Finally, Brown Brothers Harriman & Co. acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $44,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $56.61 on Wednesday. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of 14.98, a P/E/G ratio of 1.70 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a twelve month low of $51.24 and a twelve month high of $89.37. The company's fifty day moving average is $63.26 and its 200 day moving average is $62.49. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the business earned $1.22 earnings per share. The firm's revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PBH shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a report on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average target price of $76.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.